Here is the title one h1 placeholder text

Guoen Co., Ltd. disclosed the 2022 semi-annual report on the evening of August 30, the company's revenue in the first half of the year was 6.132 billion yuan, a year-on-year increase of 47.76%, a new high in the same period in history, and the net profit attributable to shareholders of listed companies was about 379 million yuan, a year-on-year increase of 7.63%, and the basic earnings per share was 1.4 yuan.

After becoming the owner of Dongbao Biotechnology last year and strategically investing in Zhejiang Yisu and Jiangsu Guoheng, the company has created a new "one body, two wings" strategic pattern with the national grace industrial platform as the center, long-term economies of scale as the goal, and the large chemical industry and the big health industry as the two wings. In the first half of the year, the company actively faced the market, integrated resources in the region, extended the industrial chain, improved the value chain, built an ecological chain, and made every effort to create a new format of high-quality development.

Actively replenish the chain, strengthen the chain and extend the chain

In terms of the large chemical sector, after the strategic investment in Zhejiang Yisu and Jiangsu Guoheng last year, the company has built a vertically integrated industrial cluster with new chemical materials as the core. In the first half of the year, with the help of the industry-leading vertical integration professional platform of new materials, the upstream and downstream industrial chains continued to improve, the product structure continued to be full, the customer group continued to be optimized, the company's scale gradually expanded, and the performance of various business segments grew steadily.

Among them, in terms of chemical raw materials, Zhejiang Yisu quickly set up a high-tech R&D process team, equipped with a full set of world-leading R&D equipment, adopted the world's advanced technology route, and has established good relations with more than 300 domestic potential customers; Jiangsu Guoheng polypropylene project with an annual output of 200,000 tons has been fully put into operation, product sales have increased steadily, and the integrated production of powder production and polypropylene modification has been initially realized.

In terms of polymer modification business, in the first half of the year, the company's business volume of customers such as black electricity, white electricity, small household appliances and power tools increased significantly, and at the same time, it actively responded to the needs of customers in the automotive business, focusing on the development of new energy vehicles, storage, lithium batteries and other product segments. The company continues to optimize the product structure, fully promote the sales of high-margin and high-tech products, strengthen internal management, improve the level of comprehensive management, and promote the steady improvement of the company's performance.

In the first half of the year, the company made new breakthroughs in business layout and customer expansion, successfully entered the field of building materials industry, reached strategic cooperation with the main enterprise of the new infrastructure industry chain, and successfully developed projects such as building formwork materials, advanced formwork support and reinforcement systems and standardized process formwork, the company's formwork material technology is at the leading level in the industry, and the supply volume continues to rise.

In terms of composite materials business, in the first half of the year, the company's newly developed products were mass-produced, and the products were continuously updated and iterated, and HP-RTM, SMC, BMC, and thermoplastic hybrid materials blossomed in many places, becoming the company's new growth point. For example, in terms of automotive SMC parts, the company continues to optimize the formula of SMC sheets, develops new modified polyurethane resin SMC materials, and opens up new material application fields for lightweight structural products.

In the first half of the year, the company focused on the development of HP-RTM preforming, glue injection, laser cutting, air tightness inspection and other related processes in the application of new energy composite chocolate ultra-thin battery packs, and has established strategic cooperation with leading enterprises in the field of new energy power batteries to carry out fixed-point layout in the field of new composite materials, which will become an important pole of the company's composite materials sector in the future.

In addition, in the first half of the year, the company also continued to make new breakthroughs in business segments such as degradable materials, light display materials, artificial turf, and medical protective materials. In terms of light display materials business, the high-brightness diffusion board has entered the experimental verification stage through independent innovation, which has achieved great support for the improvement of the brightness of the whole machine, and the artificial turf business focused on developing the Latin American market in the first half of the year, jumping from scratch to a market benchmark.

We will make every effort to promote the strategic layout of "collagen +".

After becoming the owner of Dongbao Biotechnology last year and carrying out internal industrial integration, the company's big health industry ecology has been gradually improved. As the only A-share company focusing on the whole natural collagen industry chain, in the first half of the year, Dongbao Biotech continued to carry out strategic layout around "collagen+", and its revenue and net profit both hit a new high in the same period in history: revenue of 476 million yuan, a year-on-year increase of 72.18%, and net profit of 57.9749 million yuan, a year-on-year increase of 667.73%.

In terms of gelatin, collagen and their derivatives business, Dongbao Bio's gelatin series products and by-product dicalcium phosphate have developed steadily, and the market demand has been improving, with operating income of 288 million yuan in the first half of the year, a year-on-year increase of 12.35%, gross profit of 79.4689 million yuan, a year-on-year increase of 203.54%, and gross profit margin of 27.58%, an increase of 17.37 percentage points year-on-year, and profitability has been significantly enhanced.

In the first half of the year, 43 new customers were added, and the application fields were expanded to hot pot bases, medical devices, flavor popping beads, etc., and further broadened the market application fields through product segmentation, realized the sales of special-purpose gelatin, further enhanced the added value of products, and also increased the market development of plasma gelatin.

In the first half of the year, the company continued to promote the "collagen +" layout, made every effort to promote the market promotion of terminal series products, and quickly cultivated the terminal business into a new business growth point, with the operating income of collagen series products reaching 36.9665 million yuan, a year-on-year increase of 102.2%, gross profit reaching 9.5775 million yuan, a year-on-year increase of 105.4%, and gross profit margin reaching 25.91%, an increase of 0.41 percentage points year-on-year.

In terms of product structure, the company has successively launched Yuansu series of bovine bone collagen peptide powder (instant type), compound probiotics, meal replacement shakes, collagen hydrating mask (new), etc., and bird's nest collagen peptide liquid drink, collagen bright color mask, and passion fruit enzyme powder will be launched in September. In terms of brand promotion, the company made concerted efforts online and offline, and also hired a well-known actress Liu Xiaoye to endorse the Yuansu brand (excluding health food), and the brand awareness was further enhanced.

In terms of channel construction, the company has steadily promoted the construction of sales channels for terminal series products, on the one hand, it has increased the promotion of the original online and offline channels, and on the other hand, it has built a new platform for its own private domain e-commerce in Hangzhou, Qingdao and other developed Internet areas.

In terms of biopharmaceutical excipient materials business, while exploring new foreign trade models to expand the share of international trade, Yiqing Biotech has established network sales channels, enriched customer groups, successfully developed 15 customers above designated size (more than 2 million tablets), deepened cooperation with original customers, successfully cut into new product varieties, and made new progress in cost reduction and efficiency increase, quality improvement, product upgrading, appearance improvement and other aspects through process improvement and development.